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The biologically active growth factor LPA has gained
broad interest after it was proposed as a possible marker
for ovarian cancer [1]. Although much is known about
LPA signaling, its physiological and pathological rele-
vance remains unclear. Recent data from Tokumura et al.
[2–4] may change our perception of LPA and cause LPA
researches to focus on its physiological aspects. LPA func-
tions may also be reflected in the expression of LPA pro-
ducing enzyme lysophospholipase D (LPLD), which is
increased in serum and correlates with the progress of
pregnancy [2,3]. Recent exciting data, from the same and
other groups, has recognized this enzyme as autotaxin, a
cell motility stimulating phosphodiesterase implicated in
tumor progression [3,5,6]. At first glance, it may appear
contradictory that a factor associated with tumor progres-
sion may serve normal physiological functions [7]. To ap-
preciate this better the normal physiology of reproductive
systems should be contemplated. Only a few tissues are
known to grow under normal physiological conditions
and notable among these are the ovary, endometrium,
placenta and the growing syncytiotrophoblast. Growth
and differentiation of the ovary and endometrium (/pla-
centa) is accompanied by processes which have been lik-
ened to inflammation and wound-healing.
Unfortunately, these aspects of LPA biology appear to fo-
cus the interest of reproductive biologists and gynecolo-
gists only, and not the rest of the scientific community.
Not only, are reproductive systems part of normal physio-
logical function, but also they provide amenable models
for the study of controlled growth and differentiation.
May be we should accept that the pathological role of LPA
could be a reflection of its physiological functions. In this
perspective, Autotaxin may presumably take center stage
in future drug discovery associated not only with cancer
treatment but also with fertility control.
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Figure 1
Secretory ecto-phospholipases produce biologically 
active lipid, lysophosphatidic acid (LPA). LPA should be 
released into extracellular fluid to signal through its specific 
G-protein coupled receptor (LP-R) [7]. Secretory ecto-
enzymes like Lysophospholipase D (LPLD) or secretory-type 
Phospholipase A2 (sPLA2) act on phospholipd substrates 
available in extracellular leaflets of the plasma membrane 
(and can supply LPA directly to its receptors).
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